Share This Article:

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Acute Pulmonary Embolism

Abstract Full-Text HTML Download Download as PDF (Size:116KB) PP. 58-62
DOI: 10.4236/ojemd.2012.24009    3,972 Downloads   6,537 Views  


Patients with pulmonary embolism (PE) have a high risk of death and it is important to recognize factors associated with high mortality. N-Terminal pro-Brain Natriuretic Peptide (NT-pro BNP) has recently emerged as a promising biomarker for risk assessment in acute pulmonary embolism (PE). The aim of this study is to detect the in hospital prognostic value of NT-pro BNP in patients with acute (PE). Methods: This study included 64 patients diagnosed as (PE) with the mean age of 59.1 ± 16.5 years, 40 patients of them (62.5%) were male. All patients were subjected to 12 leads ECG. X-ray chest, laboratory tests including D-Dimer, troponin I, NT-pro BNP, Doppler ultrasound for the venous system of both lower limbs, Echocardiograhy and 64 multislices CT pulmonary angiography. Results: According to the admission level of NT-pro BNP our patients were divided into two groups: group I included 22 patients with normal NT-pro BNP (less than 300 pg/ml), and group II included 42 patients with elevated NT-pro BNP (more than or equal 300 pg/ml). Patients in group II were found to have a significantly higher incidence of heart failure (28.6% Vs 4.6%, p = 0.025), impaired kidney function (serum creatinine was 1.7 ± 0.6 Vs 1.1 ± 0.2, p = 0.018), tachypnea (85.7% Vs 54.5%, p = 0.006) and cardiogenic shock (26.2% Vs 0%, p = 0.014) but a significantly lower incidence of chest pain (21.4% Vs 45.5%, p = 0.04) and lower left ventricular ejection fraction (51.3% ± 16.9% Vs 67.3% ± 12.8%, p = 0.043) compared to group I. There were a significantly higher treatment with thrombolytic therapy (35.7% Vs 9.1%, p=0.021) and positive inotropics (35.71% Vs 4.55%, p = 0.006) in group II compared to group I. Also group II had a higher need for mechanical ventilation (26.12% Vs 4.55%, p = 0.04) and a longer in hospital stay (19.5 ± 10.3 Vs 5.3 ± 4.5, p = 0.001) than group I. The in hospital mortality was significantly higher in group II compared to group I (19.05% Vs 0.0%, p = 0.042). Conclusion: Elevated NT-pro BNP levels in patients with (PE) are associated with worse short term prognosis in terms of higher morbidity and mortality and it could be used as a valuable prognostic parameter and good indicator for the need of more aggressive therapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Selem, H. Radwan and A. M Gomaa, "Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Acute Pulmonary Embolism," Open Journal of Endocrine and Metabolic Diseases, Vol. 2 No. 4, 2012, pp. 58-62. doi: 10.4236/ojemd.2012.24009.


[1] J. A. Heit, L. J. Melton, C. M. Lohse, T. M. Petterson, M. D. Silverstein, D. N. Mohr and W. M. O’Fallon, “Incidence of Venous Thromboembolism in Hospitalized Patients Vs Community Residents,” Mayo Clinic Proceedings, 2001, pp. 1102-1110. doi:10.4065/76.11.1102
[2] C. Kearon, “Natural History of Venous Thromboembolism,” Circulation, Vol. 107, No. 23 S1, 2003, pp. 22-30. doi:10.1161/01.CIR.0000078464.82671.78
[3] S. Z. Goldhaber, L. Visani and M. De Rosa, “Acute Pulmonary Embolism: Clinical Outcomes in the International Cooperative Pulmonary Embolism Registery,” Lancet, Vol. 353, No. 9162, 1999, pp. 1386-1389. doi:10.1016/S0140-6736(98)07534-5
[4] S. Konstantinides, “Pulmonary Embolism: Impact of Right Ventricular Dysfunction,” Current Opinion on Cardiology, Vol. 20, No. 6, 2005, pp. 496-501. doi:10.1097/
[5] S. Z. Glodhabber, “Pulmonary Embolism. Braunwald s Heart Disease A Textbook of Cardiovascular Medicine,” 9th Edition, Saunders, 2012.
[6] S. Z. Goldhaber, “Pulmonary Embolism,” Lancet, Vol. 363, No. 9417, 2004, pp. 1295-1305. doi:10.1016/S0140-6736(04)16004-2
[7] R. Cavallazzi, A. Nair, T. Vasu and P. E. Marik, “Natriuretic Peptides in Acute Pulmonary Embolism: A Systematic Review Published Online,” Vol. 34, No. 12, 2008, pp. 2147-2156.
[8] L. Binder, B. Pieske, M. Olschewski, A. Geibel, B. Klostermann, C. Reiner and S. Konstantinides, “N-Terminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism,” Circulation, Vol. 112, No. 11, 2005, pp. 1573-1579. doi:10.1161/CIRCULATIONAHA.105.552216
[9] N. Vuilleumier, M. Righini, A. Perrier, A. Rosset, N. Turck, J. C. Sanchez, H. Bounameaux, G. Le Gal, N. Mensi and D. Hochstrasser, “Correlation between Cardiac Biomarkers and Right Ventricular Enlargement on Chest CT in Non Massive Pulmonary Embolism,” Thombo Research, Vol. 121, No. 5, 2008, pp. 617-624. doi:10.1016/j.thromres.2007.07.003
[10] N. Kucher, G. Printzen and S. Z. Goldhaber, “Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism,” Circulation, Vol. 107, No. 20, 2003, pp. 2545-2547. doi:10.1161/01.CIR.0000074039.45523.BE
[11] W. Kasper, S. Konstantinides, A. Geibel, M. Olschewski, F. Heinrich, K. D. Grosser, K. Rauber, S. Iversen, M. Redecker and J. Kienast, “Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism: Results of a Multicenter Registry,” Journal of American College Cardiology, Vol. 30, No. 5, 1997, pp. 1165-1171. doi:10.1016/S0735-1097(97)00319-7
[12] “British Thoracic Society Guidelines for the Management of Suspected Acute Pulmonary Embolism,” Thorax, Vol. 58, No. 6, 2003, pp. 470-483. doi:10.1136/thorax.58.6.470
[13] H. Dores, C. Fonseca, S. Leal, I. Rosário, J. Abecasis, J. Monge, M. J. Correia, L. Bronze, A. Leit?o, I. Arroja, A. Aleixo and A. Silva, “NT-proBNP for Risk Stratification of Pulmonary Embolism,” Portuguese Journal of Cardiology, Vol. 30, No. 12, 2011, pp. 881-886.
[14] J. C. Lega, Y. Lacasse, L. Lakhal and S. Provencher, “Natriuretic Peptides and Troponins in Pulmonary Embolism: A Meta-Analysis,” Thorax, Vol. 64, No. 10, 2009, pp. 869-875. doi:10.1136/thx.2008.110965
[15] M. J. Agterof, R. E. Schutgens, R. J. Snijder, G. Epping, H. G. Peltenburg, E. F. Posthuma, J. A. Hardeman, R. van der Griend, T. Koster, M. H. Prins and D. H. Biesma, “Out of Hospital Treatment of Acute Pulmonary Embolism in Patients with a Low NT-proBNP Level,” Journal of Thromb Haemost, Vol. 8, No. 6, 2010, pp. 1235-1241. doi:10.1111/j.1538-7836.2010.03831.x
[16] Columbus Investigators, “Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism,” New England Journal of Medicine, 1997, Vol. 337, No. 10, pp. 657-662. doi:10.1056/NEJM199709043371001
[17] J. H. Beer, M. Burger, S. Gretener, S. Bernard-Bagattini, H. Bounameaux, “Outpatient Treatment of Pulmonary Embolism Is Feasible and Safe in a Substantial Proportion of Patients,” Journal of Thromb Haemost, 2003, Vol. 1, No. 1, pp. 186-187. doi:10.1046/j.1538-7836.2003.00005.x
[18] S. Konstantinides, A. Geibel, G. Heusel, F. Heinrich and W. Kasper, “Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin Plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism,” New England Journal of Medicine, Vol. 347, No. 15, 2002, pp. 1143-1150. doi:10.1056/NEJMoa021274
[19] T. Schmitz-Rode, U. Janssens, S. H. Duda, C. M. Erley and R. W. Günther, “Massive Pulmonary Embolism: Percutaneous Emergency Treatment by Pigtail Rotation Catheter,” Journal of American College Cardiology, Vol. 36, No. 2, 2000, pp. 375-380. doi:10.1016/S0735-1097(00)00734-8
[20] L. Aklog, C. S. Williams, J. G. Byrne and S. Z. Goldhaber, “Acute Pulmonary Embolectomy: A Contemporary Approach,” Circulation, 2002, Vol. 105, No. 12, pp. 1416-1419. doi:10.1161/01.CIR.0000012526.21603.25
[21] M. Kostrubiec, P. Pruszczyk, A. Kaczynska and N. Kucher, “Persistent NT-proBNP Elevation in Acute Pulmonary Embolism Predicts Early Death,” Clinica Chimica Acta, 2007, Vol. 382, No. 1-2, pp. 124-128. doi:10.1016/j.cca.2007.04.010

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.